ArticleNeurocritical care2026
Hematoma Volume in Apixaban vs. Rivaroxaban-Related Intracerebral Hemorrhage.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectiveAmong patients with intracerebral hemorrhage (ICH) associated with direct oral anticoagulant (DOAC) use, it is unknown whether hematoma volume differs according to DOAC agent. The primary objective of our study was to compare baseline hematoma volume between apixaban and rivaroxaban-related ICH.
methodsWe evaluated consecutive patients with apixaban- and rivaroxaban-related spontaneous ICH admitted to a tertiary hospital between 2013 and 2024. We recorded baseline hematoma volume, hematoma expansion (> 6 cc or > 33%), and hospital mortality.
resultsThe cohort comprised 136 patients (age, median [IQR] 81 [73-87] years, 68 female [50.0%]); of whom 91 (66.9%) were taking apixaban and 45 (33.1%) were taking rivaroxaban at the time of the index ICH. There were no differences in demographics, comorbidities, or antiplatelet pretreatment between apixaban and rivaroxaban. Lobar hemorrhage location was more frequent with rivaroxaban (46.7% vs. 28.6%, P = 0.037). Rivaroxaban-related ICH patients had larger median baseline hematoma volumes (22.8 [8.0-58.0] mL vs. 12.2 [2.5-31.2] mL; P = 0.003) compared with apixaban. In multivariable linear regression analysis, rivaroxaban was independently associated with larger baseline hematoma volume (standardized linear regression coefficient: 0.581 [95% CI 0.146-1.015]; P = 0.009). Hematoma expansion (40.0% vs. 23.7%; P = 0.131) and hospital mortality (40.0% vs. 29.8%; P = 0.240) were similar between rivaroxaban and apixaban.
conclusionsCompared with apixaban, rivaroxaban pretreatment was independently associated with larger baseline hematoma volume in patients with spontaneous ICH. These findings require validation in larger cohort studies.
Indexed as
Identifiers
42498894What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.